Avenda Health is the only product performed in the physician office setting, using local anesthesia. It is also the only product that integrates treatment planning with therapy, resulting in maximum precision and the best quality of life outcomes. Relative to its competitors, Avenda Health is convenient, less invasive, more precise, has fewer side effects, and is highly scalable.

Avenda Health is entering the market at a time poised for a virtual cycle of growth. As prostate MRI rapidly grows (10x in the last four years), more patients are funneled to targeted biopsy to confirm the clinically significant disease. The 90% of urologists trained to perform those biopsies represent the customer base for Avenda Health’s FLA therapy, as the procedures require nearly the same technique. As Avenda Health’s FLA therapy is used more frequently and patient outcomes improve, the value of the biopsy increases, furthering the incentive to perform biopsies.

In addition to prostate cancer treatment, Avenda Health offers other promising applications. Eventually, the company aims to apply its imaging software across the entire care pathway of prostate cancer, including diagnosis, risk stratification, staging, and treatment monitoring. Today, the software platform can be used as a diagnostic aid in segmenting and targeting the biopsy, but its cancer mapping algorithm requires biopsy-confirmed prostate cancer. Eventually, Avenda Health hopes to use detailed MRI data alongside clinical data and labs to enable the software to identify clinically significant diseases without requiring a biopsy automatically.